Radiation Pneumonitis Prophylaxis and Management

Introduction to Radiation Pneumonitis

The primary recommendation for prophylaxis against radiation pneumonitis is to optimize radiotherapy planning by limiting the V20 to below 35% and maintaining a mean lung dose (MLD) below 20 Gy, as recommended by the American Society of Clinical Oncology 1
Radiation pneumonitis risk correlates strongly with specific dose-volume parameters, including V20 constraint, mean lung dose (MLD), and contralateral lung protection, with a V20 constraint of below 35-37% of lung volume and a mean lung dose (MLD) of below 20-23 Gy 2

Patients with pre-existing interstitial lung disease are at significantly higher risk for severe and potentially lethal radiation pneumonitis, with a reported increase in risk 3
Smoking status is a significant factor, and smoking cessation should be actively encouraged as it may decrease side effects, according to the American College of Chest Physicians 3

Safe concurrent agents with radiotherapy include platinum compounds, etoposide, taxanes, and vinorelbine, which do not appear to increase radiation pneumonitis risk, as stated by the National Comprehensive Cancer Network 1
Gemcitabine is not recommended with concurrent radiotherapy due to increased risk of radiation pneumonitis, as advised by the American Society of Clinical Oncology 1
The addition of immunotherapy (durvalumab) after chemoradiotherapy has not shown a significant increase in grade 3-4 pneumonitis compared to chemoradiotherapy alone, according to the European Society for Medical Oncology 3

Symptomatic treatment of radiation pneumonitis includes inhaled β2-mimetics and oxygen supplementation as needed, with treatment of comorbidities also essential, as recommended by the American Thoracic Society 3
Overlooking interstitial lung disease and concurrent use of contraindicated agents, such as gemcitabine, are common pitfalls in management, which can be avoided by careful patient evaluation and adherence to guidelines, as emphasized by the American College of Radiology 3

Early recognition and prompt treatment of pneumonitis is essential, with inadequate planning and delayed treatment being common mistakes, as highlighted by the American Society for Radiation Oncology 3
Clinicians can significantly reduce the incidence and severity of radiation pneumonitis by carefully adhering to dose-volume constraints during radiotherapy planning and identifying high-risk patients, as recommended by the International Commission on Radiation Units and Measurements 1